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ABSTRACT
Objective To evaluate the association between common 
biomarkers, death and intensive care unit (ICU) admission 
in patients with COVID-19.
Design Retrospective cohort study. From electronic 
national registry data, we used Cox analysis and 
bootstrapping to evaluate associations between baseline 
levels of biomarkers and standardised absolute risks of 
death/ICU admission, adjusted for age and gender.
Setting All hospitals in Denmark.
Participants 1310 patients aged ≥18 years admitted to 
hospital with COVID-19 from 27th of February to 1st of 
May 2020, with available biochemistry data.
Main outcome measures A composite of death/ICU 
admission occurring within 30 days.
Results Of the 1310 patients admitted to hospital 
(54.6% men; median age 73.6 years), 352 (26.9%) 
experienced the composite endpoint and 263 (20.1%) 
died. For the composite endpoint, the absolute risks for 
moderately and severely elevated C reactive protein 
(CRP) were significantly higher, 21.5% and 39.2%, 
respectively, compared with 5.0% for those with normal 
CRP. Moderately and severely elevated leucocytes were 
significantly higher, 34.5% and 46.6% risk, respectively, 
compared with 23.2% for those with normal leucocytes. 
Moderately and severely decreased estimated glomerular 
filtration rates (eGFR) were significantly higher, 41.5% 
and 45.9% risk, respectively, compared with 30.4% for 
those with normal/mildly decreased eGFR. Normal and 
elevated ureas were significantly higher, 22.3% and 
40.6% risk, respectively, compared with 7.3% for those 
with low urea. Elevated D- dimer was significantly higher, 
31.8% risk, compared with 17.5% for those with normal 
D- dimer. Moderately and severely elevated troponins 
were significantly higher, 27.7% and 57.3% risk, 
respectively, compared with 9.4% for those with normal 
troponin. Elevated procalcitonin was significantly higher, 
52.1% risk, compared with 28.0% for those with normal 
procalcitonin.
Conclusion In this nationwide study of patients admitted 
with COVID-19, elevated levels of CRP, leucocytes, 
procalcitonin, urea, troponins and D- dimer, and low 
levels of eGFR were associated with higher standardised 
absolute risk of death/ICU admission within 30 days.
INTRODUCTION
COVID-19 caused by the novel coronavirus, 
SARS- CoV-2, has spread rapidly to become 
a worldwide pandemic resulting in an enor-
mous strain on healthcare systems globally. 
As of 20th of September 2020, the number 
of confirmed cases has surpassed 30 million, 
affecting 213 countries, although the actual 
number is likely to be much higher.1 The 
clinical course of COVID-19 is variable, but 
is typically characterised by an initial phase 
with fever or mild upper respiratory symp-
toms (though many are asymptomatic). 
Among hospitalised patients, those with a 
poor prognosis tend to develop severe viral 
pneumonia requiring ventilatory support and 
intensive care unit (ICU) admission.2 Despite 
supportive care, a high proportion of patients 
with COVID-19 suffer rapid deterioration with 
respiratory failure and death.3–5 Identifying 
which patients are at risk of severe disease or 
Strengths and limitations of this study
 ► Much of the research concerning COVID-19 de-
scribes small case studies from China and Italy, 
without clearly defined outcomes.
 ► This study is the first to report the standardised 
absolute risk of individual laboratory tests on 
short- term mortality and ICU admission in a rela-
tively large, European cohort of 1310 patients with 
COVID-19.
 ► Our study can help the clinicians to understand which 
biomarkers are important in identifying patients with 
poor prognosis, which may be useful to assess dis-
ease severity or to enable early intervention.
 ► The main limitation of our study is its observational, 
non- randomised design.
 ► This study included only patients admitted to the 
hospital with COVID-19 and measured biochemi-
cal data, hence it is likely to represent symptom-
atic patients at the more severe end of the disease 
spectrum.
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death, may be useful in decision- making, to determine 
whether hospitalisation or ICU referral is required or to 
enable early intervention.6 This is of particular impor-
tance given that the fast pace of the pandemic has led 
to rationing of scarce resources, most notably mechanical 
ventilators.7
Several studies have demonstrated that older age and 
chronic diseases are associated with poor outcome in 
patients with COVID-19.2 5 Furthermore, in a recently 
published systematic review, disease severity was asso-
ciated with more prominent laboratory abnormalities 
including markers of inflammation and organ damage 
including elevated troponins, although much of the 
early research describes small case studies without clearly 
defined outcomes and the need for further research 
in more varied cohorts was highlighted.2 8–11 A recently 
published study showed that in multivariate analysis, 
older age, higher Sequential Organ Failure Assessment 
(SOFA) score and elevated D- dimer on admission were 
independently associated with in- hospital death.5 The 
present study aims to expand on these findings and eval-
uate which biomarkers are associated with death and ICU 
admission in a large nationwide cohort.
METHODS
Data sources
This study is based on four nationwide registers: the 
Danish National Patient Register, the Civil Registration 
System, the Danish Registry of Medicinal Product Statistics 
and the database on blood samples (LABKA). These four 
nationwide registers were cross- linked on the individual 
level using the unique permanent identification number 
given to all Danish residents at birth or migration.
The Danish National Patient Register holds informa-
tion on every hospital visit in Denmark, in which each 
visit is registered with a diagnosis according to the Inter-
national Classification of Diseases, the 10th revision. 
The Civil Registration System holds information on the 
day of birth, sex and vital status. The Danish Registry of 
Medicinal Product Statistics contains information on all 
prescriptions dispensed from Danish pharmacies and is 
coded according to the Anatomical Therapeutic Chem-
ical classification system.12 The LABKA database holds 
information on blood samples from all hospital visits, 
including the emergency departments, outpatient consul-
tations and admissions to the hospital.
Study design and participants
This study included all patients with laboratory- confirmed 
COVID-19 aged 18 years and older with available 
biochemistry data, admitted to hospital between 27th of 
February 2020 and 1st of May 2020 (the first Danish case 
was recorded on 27th of February 2020). Patients were 
included on the first day of diagnosis with COVID-19 
and followed for 30 days for the combined endpoint of 
all- cause mortality and ICU admission. A subanalysis was 
also performed for the endpoint of all- cause mortality 
alone. Blood test results were obtained from electronic 
registries of laboratory data, with baseline values taken on 
admission (measured within 24 hours). We focused on 
readily available laboratory tests associated with inflam-
mation or organ damage, including C reactive protein 
(CRP), ferritin, procalcitonin, leucocyte count, estimated 
glomerular filtration rate (eGFR), urea, alanine amino-
transferase (ALAT), D- dimer and troponin (both T and 
I). The eGFR was calculated using the Modification of 
Diet in Renal Disease equation, which includes creatinine 
level, age, race and sex. In order to compare troponin 
values with different assays and reference values, a ratio 
between observed values and highest reference values was 
performed.
Statistical analysis
Categorical data were presented as counts with percent-
ages, and the statistical difference was tested using Fish-
er’s exact test. Continuous variables were presented 
as medians with the first and third quartile (Q1 and 
Q3), and the statistical difference was tested using the 
Wilcoxon rank- sum test. Cox analysis and bootstrapping 
with 100 bootstraps were used to derive age- adjusted and 
gender- adjusted standardised absolute risk and average 
treatment effects curves with 95% CIs to evaluate the 
association between individual biomarkers and the 30- day 
risk for each endpoint. The above analysis was repeated 
with stratification by typical normal/elevated ranges 
used in the clinical setting. For the stratified analysis of 
troponin, the cut- off values were defined as being moder-
ately elevated (>one to two times elevated) and severely 
elevated (>two times elevated), relative to baseline 
troponin. As part of a sensitivity analysis, we performed 
a Cox multivariate regression analysis to assess CRP in 
relation to the combined endpoint of all- cause mortality 
and ICU admission (adjusted for age, gender, diabetes, 
chronic obstructive pulmonary disease (COPD), hyper-
tension and ischaemic heart disease). A two- sided p value 
of ≤0.05 was considered statistically significant.
Data management and statistical analyses were 
conducted using R statistics (R Core Team (2020); R: a 
language and environment for statistical computing, R 
Foundation for Statistical Computing, Vienna, Austria; 
https://www. R- project. org/).
RESULTS
A total of 4444 patients with COVID-19 were identified in 
the study period. We excluded 28 patients aged below 18 
years old, 2653 patients who were not admitted to hospital 
and 453 with no available biochemistry data, leaving 1310 
patients for inclusion in the study (54.6% men; median 
age 73.6 years). Of these, 352 (26.9%) patients experi-
enced the composite endpoint and 263 (20.1%) died (see 
figure 1).
Baseline characteristics for the total cohort and stratified 
by the composite endpoint are given in table 1 (see also 
online supplemental table S1 for baseline characteristics 
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stratified by death and online supplemental table S2 strat-
ified according to availability of biochemistry). Patients 
who experienced the composite endpoint of death/
ICU admission within 30 days were more likely to be 
older, men, with a pre- existing comorbidity (diabetes, 
COPD, atrial fibrillation, hypertension or heart failure); 
currently receiving treatment with aspirin, beta- blocker, 
angiotensin II receptor blockers, loop diuretics, calcium 
channel blockers or spironolactone; with higher baseline 
values of leucocytes, urea, D- dimer, troponin or procalci-
tonin; or lower baseline values of eGFR (p≤0.044 for all). 
However, the proportion of patients who died or were 
admitted to ICU was not significantly different for those 
with prior ischaemic stroke, ischaemic heart disease, 
chronic kidney disease, cancer, or currently receiving 
treatment with non- steroidal anti- inflammatory drugs or 
thiazides.
Biomarkers and standardised absolute risk of death and ICU 
admission
C reactive protein
Higher baseline CRP was associated with higher age- 
adjusted and sex- adjusted absolute risk of death/ICU 
admission (figure 2), and death alone (online supple-
mental figure S1).
In stratified analysis, moderately elevated (upper 
reference limit to 99 mmol/L) and severely elevated 
(100–400 mmol/L) baseline CRP were associated with 
an age- adjusted and sex- adjusted absolute risk of 21.5% 
(95% CI: 18.1% to 24.9%) and 39.2% (95% CI: 35.6% to 
43.0%) for death/ICU admission within 30 days, respec-
tively, which was a significantly higher risk (both p<0.001) 
compared with those with normal CRP, absolute risk 5.0% 
(95% CI: 0.0% to 12.0%) (figure 3).
Similarly, moderately and severely elevated base-
line CRP were associated with an age- adjusted and sex- 
adjusted absolute risk of 18.1% (95% CI: 15.1% to 21.3%) 
and 28.8% (95% CI: 25.4% to 32.1%) for 30- day mortality, 
respectively, which was a significantly higher risk (both 
p<0.001) compared with those with normal CRP, absolute 
risk 6.6% (95% CI: 0.0% to 15.0%) (online supplemental 
figure S2).
In a multivariate model, elevated CRP was inde-
pendently associated with death/ICU admission after 
adjusting for age, gender, diabetes, COPD, hypertension 
and ischaemic heart disease (figure 4; online supple-
mental table S3).
Leucocytes
Higher baseline leucocyte count was associated with 
higher age- adjusted and sex- adjusted absolute risk of 
death/ICU admission (figure 2), and death alone (online 
supplemental figure S1).
In stratified analysis, moderately elevated (upper 
reference limit to 15×109/L) and severely elevated 
(15–30×109/L) baseline leucocytes were associated with 
an age- adjusted and sex- adjusted absolute risk of 34.5% 
(95% CI: 29.5% to 39.4%) and 46.6% (95% CI: 38.5% to 
54.6%) for death/ICU admission within 30 days, respec-
tively, which was a significantly higher risk (both p<0.001) 
compared with those with normal leucocytes, absolute 
risk 23.2% (95% CI: 20.4% to 22.2%) (figure 3).
In stratified analysis, moderately and severely elevated 
baseline leucocytes were associated with an age- adjusted 
and sex- adjusted absolute risk of 26.6% (95% CI: 22.0% to 
31.3%) and 37.0% (95% CI: 25.4% to 32.1%) for 30- day 
mortality, respectively, which was a significantly higher 
risk (both p<0.001) compared with those with normal 
leucocytes, absolute risk 17.6% (95% CI: 15.0% to 20.2%) 
(online supplemental figure S2).
Estimated glomerular filtration rate
Lower baseline eGFR was associated with higher age- 
adjusted and sex- adjusted absolute risk of death/ICU 
admission (figure 2), and death alone (online supple-
mental figure S1).
In stratified analysis, moderately decreased 
(30–60 mmol/L) and severely decreased (0–30 mmol/L) 
baseline eGFR were associated with an age- adjusted and 
sex- adjusted risk of 41.5% (95% CI: 35.1% to 48.0%) and 
45.9% (95% CI: 34.9% to 56.8%) for death/ICU admis-
sion within 30 days, respectively, which was a significantly 
higher risk (both p<0.001) compared with those with 
normal/mild decreased eGFR (>60 mmol/L), absolute 
risk 30.4% (95% CI: 26.7% to 34.1%) (figure 3).
In stratified analysis, moderately elevated and severely 
elevated baseline eGFR were associated with an abso-
lute risk of 34.8% (95% CI: 29.0% to 40.5%) and 42.4% 
(95% CI: 32.9% to 52.0%) for 30- day mortality, respec-
tively, (figure 3), which was a significantly higher risk 
(both p<0.001) compared with those with normal/mild 
decreased eGFR, absolute risk 22.0% (95% CI: 18.5% to 
25.5%) (online supplemental figure S2).
Urea
Higher baseline urea was associated with higher age- 
adjusted and sex- adjusted absolute risk of death/ICU 
admission (figure 2), and death alone (online supple-
mental figure S1).
Figure 1 Flowchart of study cohort. ALAT, alanine 
aminotransferase; CRP, C reactive protein; eGFR, estimated 
glomerular filtration rate.
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In stratified analysis, normal (3.6–8.0 mmol/L) and 
elevated (>8 mmol/L) baseline ureas were associ-
ated with an absolute risk of 22.3% (95% CI: 18.7% to 
25.9%) and 40.6% (95% CI: 35.5% to 45.7%) for death/
ICU admission within 30 days, respectively, which was a 
significantly higher risk (both p<0.001) compared with 
those with low urea, absolute risk 7.3% (95% CI: 1.6% to 
12.9%) (figure 3).
Table 1 Characteristics of patients with COVID-19 for total cohort, and stratified by death/ICU admission (within 30 days of 
diagnosis)
Total No death/ICU admission Death/ICU admission P value
Characteristics 1310 958 (73.1) 352 (26.9)
Age, years (median (IQR)) 73.60 (60.50–81.90) 71.15 (56.52–79.80) 77.50 (70.18–84.53) <0.001
Male sex, n (%) 715 (54.6) 489 (51.0) 226 (64.2) <0.001
Prior comorbidities
  Ischaemic stroke, n (%) 96 (7.3) 63 (6.6) 33 (9.4) 0.094
  Diabetes, n (%) 221 (16.9) 145 (15.1) 76 (21.6) 0.008
  Ischaemic heart disease, n (%) 165 (12.6) 116 (12.1) 49 (13.9) 0.398
  COPD, n (%) 135 (10.3) 86 (9.0) 49 (13.9) 0.010
  Atrial fibrillation, n (%) 212 (16.2) 132 (13.8) 80 (22.7) <0.001
  Chronic kidney disease, n (%) 131 (10.0) 88 (9.2) 43 (12.2) 0.119
  Hypertension, n (%) 474 (36.2) 323 (33.7) 151 (42.9) 0.002
  Cancer, n (%) 194 (14.8) 140 (14.6) 54 (15.3) 0.727
  Heart failure, n (%) 95 (7.3) 60 (6.3) 35 (9.9) 0.030
Prior medication
  Glimepiride, n (%) 245 (18.7) 164 (17.1) 81 (23.0) 0.017
  Aspirin, n (%) 174 (13.3) 111 (11.6) 63 (17.9) 0.004
  NSAID, n (%) 140 (10.7) 103 (10.8) 37 (10.5) 1.000
  Beta blocker, n (%) 174 (13.3) 111 (11.6) 63 (17.9) 0.004
  ACEi, n (%) 203 (15.5) 144 (15.0) 59 (16.8) 0.439
  ARB, n (%) 463 (35.3) 323 (33.7) 140 (39.8) 0.044
  Loop diuretic, n (%) 217 (16.6) 138 (14.4) 79 (22.4) 0.001
  Thiazide diuretic, n (%) 116 (8.9) 87 (9.1) 29 (8.2) 0.742
  CCB, n (%) 241 (18.4) 157 (16.4) 84 (23.9) 0.003
  Spironolactones, n (%) 69 (5.3) 41 (4.3) 28 (8.0) 0.012
Baseline laboratory values
  CRP, n (%) 1256 (95.9) 906 (94.6) 350 (99.4) <0.001
  Leucocytes, n (%) 1300 (99.2) 952 (99.4) 348 (98.9) 0.472
  eGFR, n (%) 915 (69.8) 619 (64.6) 296 (84.1) <0.001
  Urea, n (%) 1067 (81.5) 781 (81.5) 286 (81.2) 0.936
  ALAT, n (%) 1167 (89.1) 850 (88.7) 317 (90.1) 0.549
  Ferritin, n (%) 252 (19.2) 205 (21.4) 47 (13.4) 0.001
  D- dimer, n (%) 449 (34.3) 332 (34.7) 117 (33.2) 0.646
  Troponin, n (%) 258 (19.7) 197 (20.6) 61 (17.3) 0.210
  Procalcitonin, n (%) 249 (19.0) 164 (17.1) 85 (24.1) 0.005
  CRP, mg/L (median (IQR)) 88.00 (43.00–160.00) 74.50 (35.25–130.00) 131.00 (68.25–218.00) <0.001
  Leucocytes, 109/L (median (IQR)) 7.40 (5.50–10.20) 7.10 (5.30– 9.60) 8.40 (6.12–11.90) <0.001
  eGFR, mL/min/1.73m2 (median (IQR)) 73.23 (56.39–83.55) 74.80 (60.97–84.17) 66.45 (48.43–81.33) <0.001
  Urea, mmol/L (median (IQR)) 6.50 (4.60–9.60) 5.90 (4.20–8.30) 9.05 (6.60–12.47) <0.001
  ALAT, U/L (median (IQR)) 31.00 (21.00–52.00) 31.00 (21.00–51.00) 32.00 (22.00–53.00) 0.169
  Ferritin, µg/L (median (IQR)) 266.00 (143.00–446.75) 264.00 (130.00–439.00) 311.00 (189.50–464.00) 0.110
  D- dimer, mg/L (median (IQR)) 0.94 (0.55–1.80) 0.86 (0.51–1.63) 1.40 (0.77–2.40) <0.001
  Troponin ratio (median (IQR)) 1.00 (0.57–1.79) 0.92 (0.39–1.34) 2.14 (1.29–3.43) <0.001
  Procalcitonin, µg/L (median (IQR)) 0.20 (0.11–0.49) 0.15 (0.08–0.28) 0.40 (0.20–0.92) <0.001
ACEi, ACE inhibitor; ALAT, alanine aminotransferase; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; COPD, chronic obstructive pulmonary 
disease; CRP, C reactive protein; eGFR, estimated glomerular filtration rate; ICU, intensive care unit; NSAID, non- steroidal anti- inflammatory drug.
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In stratified analysis, normal and elevated baseline ureas 
were associated with an absolute risk of 15.7% (95% CI: 
11.2% to 17.4%) and 31.9% (95% CI: 26.8% to 35.4%) 
for 30- day mortality, respectively, which was a significantly 
higher risk (both p<0.001) compared with those with low 
urea, absolute risk 5.4% (95% CI: 0.0% to 11.0%) (online 
supplemental figure S2).
Alanine aminotransferase
Higher baseline ALAT was associated with slightly higher 
absolute risk of death/ICU admission (figure 2), and 
death alone (online supplemental figure S1).
In stratified analysis, elevated (>upper reference limit) 
baseline ALAT was associated with an absolute risk of 
36.9% (95% CI: 30.7% to 43.1%) for death/ICU admis-
sion within 30 days, which was significantly higher than 
normal ALAT (10 U/L to upper reference limit), absolute 
risk 26.9% (95% CI: 23.6% to 29.3%, p=0.002), however 
not significantly different to low ALAT (<10 U/L), abso-
lute risk 43.8% (95% CI: 21.1% to 66.4%) (figure 3).
In stratified analysis, low baseline ALAT was associated 
with an absolute risk of 41.0% (95% CI: 22.7% to 59.4%) 
for 30- day mortality, which was significantly higher than 
normal ALAT, absolute risk 20.8% (95% CI: 18.2% to 
23.4%, p=0.03), however not significantly different to 
high ALAT, absolute risk 25.8% (95% CI: 19.9% to 31.8%) 
(online supplemental figure S2).
Ferritin
Higher baseline ferritin was associated with an inverted U 
shaped risk of death/ICU admission (figure 2), and risk 
of death alone (online supplemental figure S1).
In stratified analysis, elevated (>300 mmol/L) base-
line ferritin was associated with an age- adjusted and sex- 
adjusted absolute risk of 22.7% (95% CI: 15.1% to 30.3%) 
for death/ICU admission within 30 days, which was not a 
significantly higher risk compared with those with normal 
ferritin (≤300 mmol/L), absolute risk 19.7% (95% CI: 
12.5% to 32.9%) (figure 3).
In stratified analysis, elevated (>300 mmol/L) base-
line ferritin was associated with an age- adjusted and sex- 
adjusted risk of 15.9% (95% CI: 0.09% to 22.8%) for 
30- day mortality, which was not a significantly higher risk 
compared with those with normal ferritin (≤300 mmol/L), 
Figure 2 A 30- day absolute risk for the composite outcome 
of death or ICU admission, adjusted for age and gender. 
ALAT, alanine aminotransferase; CRP, C reactive protein; 
eGFR, estimated glomerular filtration rate; ICU, intensive care 
unit.
Figure 3 A 30- day absolute risk for the composite outcome 
of death or ICU admission, stratified by normal/elevated 
ranges, and adjusted for age and gender. ALAT, alanine 
aminotransferase; CRP, C reactive protein; eGFR, estimated 
glomerular filtration rate; ICU, intensive care unit.
Figure 4 A 30- day absolute risk for the composite outcome 
of death or ICU admission, adjusted for CRP level, age, 
gender, diabetes, chronic obstructive pulmonary disease, 
hypertension and ischaemic heart disease. CRP, C reactive 
protein; ICU, intensive care unit.
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absolute risk 19.8% (95% CI: 12.6% to 26.9%) (online 
supplemental figure S2).
D-dimer
Higher baseline D- dimer was associated with an age- 
adjusted and sex- adjusted higher risk of death/ICU 
admission (figure 2), and risk of death alone (online 
supplemental figure S1).
In stratified analysis, elevated (>0.5 mg/L) baseline 
D- dimer was associated with an age- adjusted and sex- 
adjusted absolute risk of 31.8% (95% CI: 26.7% to 36.8%) 
for death/ICU admission within 30 days, which was a 
significantly higher risk (p<0.001) compared with those 
with normal D- dimer, absolute risk 17.5% (95% CI: 10.9% 
to 24.1%) (figure 3).
In stratified analysis, elevated baseline D- dimer was asso-
ciated with an age- adjusted and sex- adjusted risk of 19.1% 
(95% CI: 14.7% to 23.5%) for 30- day mortality, which was 
a significantly higher risk (p<0.001) compared with those 
with normal D- dimer, absolute risk 13.5% (95% CI: 8.5% 
to 19.5%) (online supplemental figure S2).
Troponin
Higher baseline troponin ratio was associated with age- 
adjusted and sex- adjusted higher risk of death/ICU 
admission (figure 2), and risk of death alone (online 
supplemental figure S1).
In stratified analysis, moderately elevated and severely 
elevated baseline troponins were associated with an age- 
adjusted and sex- adjusted absolute risk of 27.7% (95% CI: 
16.5% to 38.9%) and 57.3% (95% CI: 43.3% to 71.3%) for 
death/ICU admission within 30 days, respectively, which 
was a significantly higher absolute risk (p=0.003 and 
p<0.001, respectively) compared with those with normal 
troponins, absolute risk 9.4% (95% CI: 4.2% to 14.5%) 
(figure 3).
In stratified analysis, moderately elevated and severely 
elevated baseline troponins were associated with an age- 
adjusted and sex- adjusted absolute risk of 10.8% (95% CI: 
3.2% to 18.5%) and 35.9% (95% CI: 23.2% to 48.6%) for 
30- day mortality, respectively. However, only the latter was 
a significantly higher risk (p<0.001) compared with those 
with normal troponins, absolute risk 3.9% (95% CI: 0.0% 
to 8.7%) (online supplemental figure S2).
Procalcitonin
Higher baseline procalcitonin was associated with age- 
adjusted and sex- adjusted higher risk of death/ICU 
admission (figure 2), and risk of death alone (online 
supplemental figure S1).
In stratified analysis, elevated (>0.5 µg/L) baseline 
procalcitonin was associated with an age- adjusted and 
sex- adjusted risk of 52.1% (95% CI: 41.5% to 62.6%) 
for death/ICU admission within 30 days, which was a 
significantly higher risk (p<0.001) compared with those 
with normal procalcitonin, absolute risk 28.0% (95% CI: 
21.1% to 34.9%) (figure 3).
In stratified analysis, elevated baseline procalcitonin 
was associated with an age- adjusted and sex- adjusted abso-
lute risk of 29.5% (95% CI: 19.9% to 39.0%) for 30- day 
mortality, which was a significantly higher absolute risk 
(p=0.03) compared with those with normal procalcitonin, 
absolute risk 18.0% (95% CI: 12.0% to 24.0%) (online 
supplemental figure S2).
DISCUSSION
This nationwide study is the first of its kind to examine 
the association between common biomarkers and risk 
of early death and ICU admission in adult patients 
admitted to hospital with laboratory- confirmed COVID-
19. In particular, the inflammatory markers CRP, leuco-
cytes and procalcitonin, and markers of organ damage 
including eGFR, troponins and D- dimer are associated 
with higher risk of death/ICU admission within 30 days. 
However, the association between ferritin and ALAT was 
non- significant.
The novelty of the SARS- CoV-2, coupled with the 
rapid spread of the COVID-19 pandemic, has led to a 
tremendous burden on healthcare systems worldwide. 
To provide optimal care for patients, early diagnosis and 
identification of vulnerable patients who are at risk of 
severe disease is needed, as well as recognising patients 
who may rapidly deteriorate and require ICU admission 
and mechanical ventilation. This relies on an accurate 
knowledge of the critical clinical predictors for disease 
progression in order to triage patients and allocate scarce 
resources efficiently. This is especially important when 
considering which patients should start treatment. For 
example, in the first trial to offer an effective treatment 
for COVID-19 disease, results showed that early adminis-
tration of antiviral treatment with remdesivir was superior 
to placebo in reducing time to recovery and in particular, 
the authors highlighted the need to start antiviral treat-
ment before pulmonary disease progresses to require 
mechanical ventilation.13
In the present study, patients who died or were admitted 
to ICU were more likely to be older, men and with a pre- 
existing comorbidity, which is consistent with observed 
global trends. Our results are aligned with a recent large 
cohorts of patients hospitalised with COVID-19 in the UK 
and USA, as well as meta- analysis of studies from China.2 14 
The median age of patients who died in our study was 81 
years, similar to the values noted in the UK study (median 
80 years) but much older compared with patients included 
in the early studies from the Wuhan region. Similarly, we 
reported a greater proportion of death/ICU admission 
among men (64%) and patients with pre- existing comor-
bidity (prior diabetes, COPD, atrial fibrillation and hyper-
tension). Differences are most likely due to a variety of 
factors including regional differences concerning demo-
graphics, preparedness and knowledge of COVID-19 that 
have drawn on experience from China and other coun-
tries as the outbreak has spread.
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In terms of clinical laboratory biomarkers, recent 
systematic reviews of the literature have highlighted many 
of the challenges inherent in the early studies of COVID-
19, as many of the early studies are limited by the small size 
of the study populations with regional bias (most data are 
confined to China and Italy), and with limited or poorly 
defined outcomes.6 11 Several studies have evaluated level 
of individual biomarkers in small and selected COVID-19 
cohorts. An Italian study, including 239 patients, reported 
that several laboratory parameters including elevated 
lymphocytes, procalcitonin, interleukin-6, ferritin, CRP 
and ALAT were associated with death and ICU admission 
in unadjusted Cox analysis. However, in adjusted analysis, 
CRP was the only biomarker associated with increased 
risk of death/ICU admission.15
An early meta- analysis identified a range of abnormal 
biomarkers that was elevated in patients with COVID-19 
who died, including elevated levels of inflammatory 
markers and acute phase reactants such as interleukin-6, 
CRP, ferritin, lymphopenia, as well as reduced CD4 and 
CD8 counts and coagulation abnormalities including 
prolonged PT, increased D- dimer and thrombocyto-
penia.16 We were able to expand on these findings, 
reporting age- adjusted and gender- adjusted absolute risk 
of death/ICU admission of individual biomarkers in a 
larger, European cohort. In the present study inflamma-
tory markers such as CRP, leucocytes and procalcitonin, 
and markers of organ damage including eGFR, urea, 
troponins and D- dimer were associated with higher risk of 
death/ICU admission within 30 days. However, the associ-
ation between ferritin and ALAT was non- significant. The 
association with inflammatory markers and acute phase 
reactants likely reflects the cytokine storm associated with 
severe infection and subsequent end- organ damage from 
severe sepsis.17 However, it is also essential to recognise 
that the acute phase reactants are non- specific markers 
of inflammation. For example, procalcitonin secretion 
is not induced by gamma- interferon (produced mainly 
in response to viral infections), making it primarily an 
attractive marker of bacterial infections.18 Nevertheless, 
bacterial superinfection is an important consideration in 
COVID-19; for example, in the study by Wang et al, 81.7% 
of patients who died with COVID-19 had an associated 
bacterial infection.19 Probably, patients with longer and 
more complex admissions or ICU treatment are more 
vulnerable to secondary infections for example, ventilator- 
acquired infection, with an expected rise in procalcitonin 
levels. Accordingly, Zhou et al observed that half of the 
non- survivors experienced a secondary infection, with 
almost one- third due to ventilator- associated pneumonia.5 
However, the association between higher absolute risk 
of death/ICU admission and elevated baseline procalci-
tonin in the present study suggests that early concomi-
tant bacterial infection (not only secondary infection) is 
a significant factor in adverse prognosis for patients with 
COVID-19 that clinicians should be aware of.
In the study including 191 patients from Wuhan 
region, leucocytes, older age, higher SOFA score and 
a higher D- dimer (greater than 1 µg/L on admission) 
were all associated with in- hospital mortality in patients 
with COVID-19.5 Although the SOFA score is mainly a 
diagnostic marker of sepsis and septic shock, it may 
reflect the state and degree of multiorgan dysfunc-
tion due to infection in general.20 In the present study, 
abnormal values of biomarkers reflecting organ damage 
including troponin, eGFR, urea and D- dimer were all 
associated with higher absolute risk of 30- day mortality 
and ICU admission. Myocarditis is a known morbidity 
among patients with COVID-19.21 Elevated troponin may 
reflect myocardial injury among patients with COVID-19, 
including direct damage to the cardiomyocytes, systemic 
inflammation, myocardial interstitial fibrosis, coronary 
plaque destabilisation and hypoxia.21 Furthermore, 
patients with cardiovascular disease are more likely to 
be admitted with COVID-19, with greater risk of cardiac 
involvement as their symptoms develop.22 With respect 
to the abnormalities observed in D- dimer, research 
suggests that respiratory failure in COVID-19 is not only 
related to development of the acute respiratory distress 
syndrome, but also due to microvascular thrombotic 
processes, which are associated with elevated D- dimer.23 
Finally, beyond the high mortality observed in those with 
organ dysfunction and respiratory failure, a generalised 
coagulopathy has also been noted in those with poor 
prognosis.24
Strengths and limitations
The main strength of this study is the completeness of 
data from a nationwide, European cohort and the avoid-
ance of selection bias resulting from race, age, sex, 
socioeconomic status, affiliation to selected hospitals or 
healthcare systems. The Danish National Patient Registry 
and the Danish Registry of Medicinal Product Statistics 
are known to be accurate.25 26 The main limitation of our 
study is its observational non- randomised design. There 
is a lack of information about important clinical param-
eters, including blood pressure, body mass index and 
smoking habits.
This study included only patients admitted to the 
hospital with COVID-19 and with measured baseline 
biochemical data. Therefore, it is likely to represent 
symptomatic patients, who are more likely to be elderly 
or with more comorbidities and at the more severe end 
of the disease spectrum. Furthermore, patients in the 
cohort may present to hospital at differing stages of their 
disease. A large proportion of patients with confirmed 
COVID-19 in Denmark had missing biochemistry data, 
which most likely represent patients who attended the 
emergency room with mild symptoms, which did not 
warrant admission or blood tests, and were not included 
in this study, thus leading to selection bias and limiting 
generalisability. Some biomarkers (particularly D- dimer, 
troponin and procalcitonin) are likely to be measured 
in those with the most severe disease (confounding by 
indication).
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CONCLUSIONS
In this nationwide study of patients admitted with COVID-
19, elevated levels of CRP, leucocytes, procalcitonin, urea, 
troponins and D- dimer, and low levels of eGFR were asso-
ciated with higher standardised absolute risk of death/
ICU admission within 30 days.
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